Trump’s Federal Marijuana Rescheduling: What It Means for Mississippi’s Medical Cannabis Program

President Donald Trump recently signed an executive order that changes the federal classification of medical marijuana, moving it from Schedule I — the strictest category reserved for drugs with no accepted medical use — to a less restrictive Schedule III. This shift, signed by acting Attorney General Todd Blanche on April 23, is being hailed as a step toward better patient care and more reliable medical research.

“This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” Blanche said in a statement.

But let’s be clear: Trump did not legalize marijuana nationwide. The drug remains illegal under federal law, and this executive order only reduces penalties related to medical marijuana. An expedited hearing is scheduled for June 29 to consider further reclassification, a process initiated under President Joe Biden’s administration.

Mississippi’s medical marijuana program stands to benefit from this federal policy tweak. Operators in the state’s medical cannabis industry can now file business deductions on their federal taxes, a relief that could boost the sector’s growth. It should also pave the way for expanded research opportunities, a crucial factor for advancing treatment options.

Medical marijuana is legal in Mississippi through the state’s Medical Cannabis Program for patients with qualifying conditions such as cancer, glaucoma, and Parkinson’s disease. Patients must obtain a medical cannabis card issued by the state and can purchase products at approved dispensaries. Non-residents can also apply for temporary medical marijuana cards under strict limits.

However, recreational marijuana remains illegal in Mississippi, with penalties still on the books for possession. Despite growing public support nationwide — a 2025 Gallup poll found 64% of Americans favor legalization — Mississippi’s political leadership remains cautious. More than 20 Republican senators, including Mississippi’s Cindy Hyde-Smith, pushed back against federal reclassification efforts, labeling marijuana “harmful to its users.”

This federal shift in marijuana policy is part of a broader pattern of Trump-era executive orders that reshape drug enforcement without congressional approval. While it does not dismantle the federal prohibition on recreational marijuana, it signals a cautious move toward loosening restrictions that have long hindered medical use and research.

For Mississippi patients and businesses navigating a patchwork of state and federal laws, this change offers a glimmer of progress — but the fight for full legalization and reform continues.